Julia P Gregory sold $529k of NRIX
director at Nurix Therapeutics, Inc.. 22,583 shares at an average of $23.40, traded Oct 14, 2026, filed Oct 14, 2026.
Score components
This filing reached EDGAR on Oct 14, 2026, so its score and components open to free visitors on Oct 21, 2026. The trade itself, the rows in the filing and the price context are public now.
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001226675-26-000006, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 14, 2026 | MOption exercise Common Stock | +22,583 | $1.86 | $42k | 33,333 | 52 min ago |
| Oct 14, 2026 | SOpen-market sale Common Stock | -22,583 | $23.40 | $529k | 10,750 | 52 min ago |
| Oct 14, 2026 | MOption exercise Director Stock Option (right to buy)derivative | -22,583 | $0.00 | $0 | 0 | 52 min ago |
Related signals
Other insiders at Nurix Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 9Weak | Nurix Therapeutics, Inc. | Christine Ring Chief Legal Officer | $134k 5,786 shares | -39% | |
| 9Weak | Nurix Therapeutics, Inc. | Christine Ring Chief Legal Officer | $149k 5,787 shares | -39% | |
| 0Weak | Nurix Therapeutics, Inc. | Gwenn Hansen Chief Scientific Officer | $37k 1,452 shares | -1% | |
| 20Weak | Nurix Therapeutics, Inc. | Gwenn Hansen Chief Scientific Officer | $100k 4,111 shares | -3% | |
| 5Weak | Nurix Therapeutics, Inc. | Gwenn Hansen Chief Scientific Officer | $109k 4,356 shares | -4% | |
| 32Weak | Nurix Therapeutics, Inc. | Hans van Houte Chief Financial Officer | $116k 4,761 shares | -11% | |
| 31Weak | Nurix Therapeutics, Inc. | Christine Ring Chief Legal Officer | $382k 16,589 shares | -65% | |
| 24Weak | Nurix Therapeutics, Inc. | Gwenn Hansen Chief Scientific Officer | $90k 3,847 shares | -3% | |
| 29Weak | Nurix Therapeutics, Inc. | Christine Ring Chief Legal Officer | $90k 3,847 shares | -16% | |
| 30Weak | Nurix Therapeutics, Inc. | Hans van Houte Chief Financial Officer | $67k 2,845 shares | -6% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.